Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.

ABSTRACT: The global spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the associated disease COVID-19, requires therapeutic interventions that can be rapidly identified and translated to clinical care. Traditional drug discovery methods have a >90% failure rate and can take 10 to 15 y from target identification to clinical use. In contrast, drug repurposing can significantly accelerate translation. We developed a quantitative high-throughput screen to identify efficacious agents against SARS-CoV-2. From a library of 1,425 US Food and Drug Administration (FDA)-approved compounds and clinical candidates, we identified 17 hits that inhibited SARS-CoV-2 infection and analyzed their antiviral activity across multiple cell lines, including lymph node carcinoma of the prostat

SUBMITTER: Mirabelli C 

PROVIDER: S-EPMC8433531 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature